Quoin Pharmaceuticals gets FDA Fast Track for QRX003 in Peeling Skin Syndrome
FDA granted Fast Track Designation for QRX003 to treat Peeling Skin Syndrome. Quoin plans to start a Phase 2/3 study in 2H 2026.
Story updates
12:34:19 PM UTC
SquawkNews
Quoin Pharmaceuticals Ltd. received FDA Fast Track Designation for QRX003 to treat Peeling Skin Syndrome and plans to start a Phase 2/3 study in 2H 2026.Material DetailsContext by AI AnalystThis extends QRX003’s regulatory momentum, adding Fast Track in PSS on top of prior designations in Netherton…